Citation: Da. Freund et Br. Luce, THE ROLE OF GOVERNMENT AND PRIVATE INSURERS IN GUIDING AND IMPLEMENTING PHARMACOECONOMIC ANALYSES, PharmacoEconomics, 13(4), 1998, pp. 383-387
Citation: Sd. Ramsey et al., THE LIMITED STATE OF TECHNOLOGY-ASSESSMENT FOR MEDICAL DEVICES - FACING THE ISSUES, American journal of managed care, 4, 1998, pp. 188-199
Authors:
SIEGEL JE
TORRANCE GW
RUSSELL LB
LUCE BR
WEINSTEIN MC
GOLD MR
Citation: Je. Siegel et al., GUIDELINES FOR PHARMACOECONOMIC STUDIES - RECOMMENDATIONS FROM THE PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE, PharmacoEconomics, 11(2), 1997, pp. 159-168
Citation: Br. Luce et Al. Hillman, WHEN IS A COST-EFFECTIVENESS CLAIM VALID - HOW MUCH SHOULD THE FDA CARE, American journal of managed care, 3(11), 1997, pp. 1660-1666
Authors:
WEINSTEIN MC
SIEGEL JE
GARBER AM
LIPSCOMB J
LUCE BR
MANNING WG
TORRANCE GW
Citation: Mc. Weinstein et al., PRODUCTIVITY COSTS, TIME COSTS AND HEALTH-RELATED QUALITY-OF-LIFE - ARESPONSE TO THE ERASMUS GROUP, Health economics, 6(5), 1997, pp. 505-510
Citation: A. Lyles et al., MANAGED CARE PHARMACY, SOCIOECONOMIC ASSESSMENTS AND DRUG ADOPTION DECISIONS, Social science & medicine, 45(4), 1997, pp. 511-521
Authors:
SULLIVAN S
ELIXHAUSER A
BUIST AS
LUCE BR
EISENBERG J
WEISS KB
Citation: S. Sullivan et al., NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM WORKING GROUP-REPORTON THE COST-EFFECTIVENESS OF ASTHMA CARE, American journal of respiratory and critical care medicine, 154(3), 1996, pp. 84-95
Citation: Br. Luce, WORKING TOWARD A COMMON CURRENCY - IS STANDARDIZATION OF COST-EFFECTIVENESS ANALYSIS POSSIBLE, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 19-22
Citation: Br. Luce et Re. Brown, THE USE OF TECHNOLOGY-ASSESSMENT BY HOSPITALS, HEALTH MAINTENANCE ORGANIZATIONS, AND 3RD-PARTY PAYERS IN THE UNITED-STATES, International journal of technology assessment in health care, 11(1), 1995, pp. 79-92
Citation: Br. Luce et K. Simpson, METHODS OF COST-EFFECTIVENESS ANALYSIS - AREAS OF CONSENSUS AND DEBATE, Clinical therapeutics, 17(1), 1995, pp. 109-125
Citation: Da. Revicki et Br. Luce, METHODS OF PHARMACOECONOMIC EVALUATION OF NEW MEDICAL TREATMENTS IN PSYCHIATRY, Psychopharmacology bulletin, 31(1), 1995, pp. 57-65
Authors:
LUCE BR
SINGER JW
WESCHLER JM
BUCKNER CD
SHEINGOLD SH
SHANNONDORCY K
APPELBAUM FR
NEMUNAITIS J
Citation: Br. Luce et al., RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOID CANCER - AN ECONOMIC-ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, PharmacoEconomics, 6(1), 1994, pp. 42-48
Authors:
DELISSOVOY G
ELIXHAUSER A
LUCE BR
WESCHLER J
MOWERY P
REBLANDO J
SOLOMKIN J
Citation: G. Delissovoy et al., COST-ANALYSIS OF IMIPENEM-CILASTATIN VERSUS CLINDAMYCIN WITH TOBRAMYCIN IN THE TREATMENT OF ACUTE INTRAABDOMINAL INFECTION, PharmacoEconomics, 4(3), 1993, pp. 203-214
Authors:
ELIXHAUSER A
LUCE BR
TAYLOR WR
REBLANDO J
Citation: A. Elixhauser et al., HEALTH-CARE CBA CEA - AN UPDATE ON THE GROWTH AND COMPOSITION OF THE LITERATURE, Medical care, 31(7), 1993, pp. 101900001-101900011